Kovaltry
Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues
Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues
Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use
The rare bleeding disorder affects approximately 800,000 people globally
Bayer’s Kerendia granted FDA approval for new heart failure indication
Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%
Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi
Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors
Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B
More than 11,800 people were living with the genetic blood disorders in the UK in 2023/2024
Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours
The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway
FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate
The progressive neurodegenerative disease affects more than ten million people worldwide
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases
Bayer UK launches digital educational hub to improve menopause support
An estimated 13 million women in the UK are currently perimenopausal or menopausal
Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial
Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy
Novo Nordisk invests $1.2bn to establish rare disease production facility in Denmark
The site will be designed to accommodate multiple product types within rare diseases
Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients
The genetic blood disorder affects more than 800,000 people globally